Literature DB >> 11137251

Humoral and cell-mediated immunity to vero cell-derived influenza vaccine.

P Brühl1, A Kerschbaum, O Kistner, N Barrett, F Dorner, M Gerencer.   

Abstract

A candidate trivalent influenza whole virus vaccine produced in a continuous mammalian cell line (Vero), and analogous commercially available egg-derived vaccines, were compared for their ability to induce humoral and cell-mediated immunity in Balb/c mice. Substantial haemagglutination-inhibition titre and high levels of influenza virus-specific IgG were found in all groups of immunized mice, irrespective of the vaccine formulation. The IgG responses were predominantly of IgG1 and IgG2a/2b isotypes. Virus-specific secretory IgA antibodies were detected only in mice immunized intranasally with a live virus, derived either from Vero cells or eggs. T-cell proliferative responses and T-helper 1 type cytokine release was significantly higher in mice immunized with Vero cell-derived influenza vaccine compared to egg-derived vaccine formulations. We have demonstrated that the immunogenicity of the trivalent Vero cell-derived whole influenza virus vaccine was comparable to that of the equivalent egg-derived vaccine, with respect to humoral immune response and was superior with respect to cellular response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11137251     DOI: 10.1016/s0264-410x(00)00316-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  Cell culture-based influenza vaccines: A necessary and indispensable investment for the future.

Authors:  Nagendra R Hegde
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  An improved reverse genetics system for influenza A virus generation and its implications for vaccine production.

Authors:  Gabriele Neumann; Ken Fujii; Yoichiro Kino; Yoshihiro Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-02       Impact factor: 11.205

Review 3.  Cell-based influenza vaccines: progress to date.

Authors:  Jennifer M Audsley; Gregory A Tannock
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  Influenza A virus lacking M2 protein as a live attenuated vaccine.

Authors:  Shinji Watanabe; Tokiko Watanabe; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

5.  Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics.

Authors:  Hiroichi Ozaki; Elena A Govorkova; Chenghong Li; Xiaoping Xiong; Robert G Webster; Richard J Webby
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

6.  Downstream Processing: From Egg to Cell Culture-Derived Influenza Virus Particles.

Authors:  M W Wolff; U Reichl
Journal:  Chem Eng Technol       Date:  2008-05-27       Impact factor: 1.728

Review 7.  The role of reverse genetics in the development of vaccines against respiratory viruses.

Authors:  G A Marsh; G A Tannock
Journal:  Expert Opin Biol Ther       Date:  2005-03       Impact factor: 4.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.